-

Half-Year Liquidity Contract Statement for Valerio Therapeutics

PARIS--(BUSINESS WIRE)--Regulatory News:

Under the liquidity contract entered into between VALERIO THERAPEUTICS (Paris:ALVIO) and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30, 2024:

- 392,365 shares
- € 144,905.34
- Number of executions on buy side on semester: 108
- Number of executions on sell side on semester: 95
- Traded volume on buy side on semester: 128,013 shares for € 15,133.69
- Traded volume on sell side on semester: 103,822 shares for € 12,955.33

As a reminder:

  • the following resources appeared on the last half year statement on 31 December 2023 on the liquidity account:

- 368,174 shares
- € 144,918.05
- Number of executions on buy side on semester: 324
- Number of executions on sell side on semester: 244
- Traded volume on buy side on semester: 304,205 shares for € 69,976.87
- Traded volume on sell side on semester: 223,191 shares for € 56,117.81

  • the following resources appeared on the liquidity account when the activity started:

- 87,612 shares
- € 196,423.24

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22, 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

Public limited company with a capital of € 21,610,998.20
Registered office: 49 boulevard du Général Martial Valin - 75015 Paris
410 910 095 R.C.S. on the Paris Trade and Companies Register

Contacts

Valerio Therapeutics
Investor Relations
investors@valeriotx.com
tel : +33 (0) 1 70 38 33 99

VALERIO THERAPEUTICS

BOURSE:ALVIO
Release Versions
EnglishFrench

Contacts

Valerio Therapeutics
Investor Relations
investors@valeriotx.com
tel : +33 (0) 1 70 38 33 99

More News From VALERIO THERAPEUTICS

Valerio Therapeutics Completes Acquisition of Etherna Immunotherapies, Building an Integrated Targeted RNA Platform to Accelerate Progress Toward the Clinic

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces the completion of the acquisition of 100% of the share capital and voting rights of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"). Further to the closing of the cash consideration of the Acquisition which occurred in August1, the Company has now proceeded to...

Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a pioneering biotechnology company in the field of next-generation precision therapies (“Valerio”, or the “Company”), provides an update on its operations and presents its financial results for the half-year ended 30 June 2026. “The first half of 2026 marked a decisive milestone in the consolidation of our strategic refocusing and in the transformation of Valerio Therapeutics. The operational launc...

Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors 

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces the signing of a definitive share purchase agreement (the "SPA") and of the related contribution agreement (the "Contribution Agreement") for the acquisition of 100% of the share capital and voting rights of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"), ba...
Back to Newsroom